Skip to the rundown
GetYourBrief Biotech desk · week of Jun 22
Search

Week brief · June 22 to 28, 2026

Biotech news, week of June 22, 2026

In the week of June 22 to 28, 2026 the Biotech desk recorded 19 news events on 7 days. Clinical trial led with 8.

The most covered stories of the week

  1. Jun 24 White House requests $87.6 billion from Congress, mostly for Iran war 16
  2. Jun 23 Kennedy says US should lead in medical research and innovation 6
  3. Jun 22 Gut researchers say microbiome product claims outpace evidence 5
  4. Jun 22 Cogent Biosciences presents preclinical data for CGT1145 2
  5. Jun 22 Nigeria Lassa fever deaths reach 214, NCDC says 2
  6. Jun 22 Aurobindo Pharma US gets FTC nod for $250 million Lannett acquisition 2
  7. Jun 23 Lexaria says animal study GLP-1-A26-1 began dosing on schedule 2
  8. Jun 23 Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention 2
  9. Jun 28 Cassidy accuses RFK Jr. of building public health on a foundation of lies 2

Monday, June 22, 2026

4 events. The full rundown for June 22, 2026. The most covered:

  1. 15:45 UTC Gut researchers say microbiome product claims outpace evidence 5
  2. 14:45 UTC Cogent Biosciences presents preclinical data for CGT1145 2
  3. 09:45 UTC Nigeria Lassa fever deaths reach 214, NCDC says 2

Tuesday, June 23, 2026

6 events. The full rundown for June 23, 2026. The most covered:

  1. 22:00 UTC Kennedy says US should lead in medical research and innovation 6
  2. 13:45 UTC Lexaria says animal study GLP-1-A26-1 began dosing on schedule 2
  3. 12:45 UTC Cognivia-Mayo Collaboration Targets 3 Behavioral Drivers to Improve Trial Retention 2

Wednesday, June 24, 2026

  1. 01

    White House requests $87.6 billion from Congress, mostly for Iran war

    16 outlets · first: citizensvoice.com Funding

    Reported by citizensvoice.com, yahoo.com, wdsu.com, stcatharinesstandard.ca, nydailynews.com, mynorthwest.com, and 10 more outlets.

    Full coverage: every report, when each was published, and who was named (16 outlets)

  2. 02

    Biosidus signs licensing and supply agreement with Mubadala Bio

    1 outlet · first: Pr Newswire Pharma Mostly press releases

    Machine summary Biosidus, an Argentina-headquartered biotechnology company, and Mubadala Bio, Mubadala Investment Company's life sciences platform, announced a licensing and supply agreement to bring biologic therapies to the UAE through DiabTec, Mubadala Bio's biologics platform, prnewswire.com reported. The companies said the therapies cover endocrinology, nephrology and oncology and include epoetin alfa, filgrastim, interferon beta and somatropin.

    Reported by Pr Newswire.

    • Mubadala Investment Company
    • epoetin alfa
    • Mubadala Bio
    • filgrastim
    • interferon beta
    • DiabTec

Thursday, June 25, 2026

  1. 03

    H.B. Fuller agrees to acquire UK-listed AMS for £659 million

    1 outlet · first: Bloomberg Acquisition

    Reported by Bloomberg.

    • H.B. Fuller Co.

Saturday, June 27, 2026

  1. 05

    Pfizer's 6.9% dividend yield draws attention as stock trades below pre-pandemic levels

    1 outlet · first: fool.com Pharma

    Machine summary An opinion piece reports that Pfizer offers a 6.9% dividend yield, with its stock price roughly 60% below its late 2021 high and lower than before the coronavirus pandemic. The article states Pfizer's dividend payout ratio is 130% and that the company abandoned a GLP-1 weight-loss drug in 2025.

    1. Pfizer is offering dividend investors a 6.9% yield, according to the opinion piece.
    2. The S&P 500 index has a 1% yield and the average pharmaceutical stock's yield is 1.6%, the article states.
    3. Pfizer's stock price is roughly 60% below its late 2021 high and lower than before the coronavirus pandemic, the article reports.
    4. According to the article, Pfizer was compelled to give up a GLP-1 weight-loss drug that it was developing in 2025.
    5. Pfizer's dividend payout ratio sits at 130%, the article states.

    Reported by fool.com.

Sunday, June 28, 2026

  1. 06

    Cassidy accuses RFK Jr. of building public health on a foundation of lies

    2 outlets · first: cbsnews.com Pharma

    Machine summary Sen. Bill Cassidy, who chairs the Senate health committee, said on "Face the Nation with Margaret Brennan" that commitments HHS Secretary Robert F.

    1. Cassidy said: "If you build public health upon a foundation of lies, then you're going to have the absence of adequate public health."
    2. Asked whether Kennedy has restored trust in public health, Cassidy said, "He has not restored trust in public health."

    Reported by cbsnews.com and yahoo.com.

  2. 07

    SCOTUS holds FIFRA expressly preempts state law failure-to-warn claims

    1 outlet · first: National Law Review Fda approval

    Machine summary Key facts from the reports:

    1. The Supreme Court ruled 7-2 that FIFRA expressly preempts state failure-to-warn claims requiring a cancer warning on Roundup that EPA had not mandated.
    2. The decision resolves a circuit split, holding that FIFRA's uniformity provision (7 U.S.C. § 136v(b)) bars state tort claims seeking additional or different labeling.

    Reported by National Law Review.

    • Roundup

More events reported

No summary of ours and no outlet headline passed our automated checks for these, which says nothing about the events (how they work); the outlets and their reports are linked.

Friday, June 26, 2026

  1. · 2 outletsusa.chinadaily.com.cn, europe.chinadaily.com.cn
  2. · 2 outletsBloomberg, Seeking Alpha

Summaries and key facts are machine summaries of the reports linked with them; outlets, times and counts come from those reports. How a rundown is built.

What kind of news was it?

  1. Clinical trial 8
  2. Pharma 5
  3. Acquisition 2
  4. Funding 1
  5. Fda approval 1

Sources: the outlets' reports linked on this page; counts and times from GetYourBrief's record of those reports (methodology).